What are the recommended dosing, titration schedule, contraindications, monitoring parameters, and alternative therapies for donepezil in Alzheimer’s disease?

Donepezil for Alzheimer's Disease

Start donepezil at 5 mg once daily in the evening, increase to 10 mg after 4-6 weeks, and consider 23 mg only in moderate-to-severe disease after at least 3 months on 10 mg. 1

Dosing and Titration

Initial Dosing

• Start with 5 mg once daily in the evening, just prior to retiring 2, 1
• Can be taken with or without food, though taking with food reduces gastrointestinal side effects 2

Dose Escalation Algorithm

For Mild to Moderate Alzheimer's Disease:

• Maintain 5 mg daily for 4-6 weeks minimum before considering escalation 2, 1
• Increase to 10 mg once daily (maximum dose for this population) 1

For Moderate to Severe Alzheimer's Disease:

• Start at 5 mg daily for 4-6 weeks 1
• Escalate to 10 mg daily for at least 3 months 1
• Consider 23 mg daily only after this period if:
  • Patient tolerates 10 mg well
  • Continued cognitive decline despite 10 mg dose
  • Advanced disease severity 3

Critical titration note for 23 mg: Use intermediate dose titration (15 mg for 4 weeks OR alternating 10/23 mg for 4 weeks) before escalating to 23 mg to reduce cholinergic side effects, particularly nausea 4

Contraindications

• Known hypersensitivity to donepezil or piperidine derivatives 1

Monitoring Parameters

Assessment of Response

Evaluate treatment response at 6-12 months using 2:

• Physician's global assessment
• Primary caregiver report
• Neuropsychologic assessment or mental status questionnaire (though brief tests are relatively insensitive)
• Evidence of behavioral or functional changes

Discontinuation Criteria

Stop donepezil if 5:

• Clinically meaningful worsening over 6 months despite treatment (in absence of delirium or acute illness)
• No benefit observed at any time during treatment
• Severe/end-stage dementia with dependence in most basic ADLs
• Intolerable side effects develop and persist
• Poor medication adherence

Cardiovascular Monitoring

• Monitor for bradycardia and heart block, particularly in patients with underlying cardiac conduction abnormalities 1
• Watch for syncopal episodes 1

Gastrointestinal Monitoring

• Most common side effects: nausea, vomiting, diarrhea 2, 1
• Higher incidence with 10 mg vs 5 mg, and markedly higher with 23 mg (11.8% nausea vs 3% on 10 mg) 1
• Monitor for GI bleeding, especially in patients at increased risk for ulcers 1
• Watch for anorexia and weight loss, particularly with 23 mg dose 1, 6

Other Monitoring

• Initial agitation may occur in first few weeks but typically subsides 2
• No hepatic monitoring required (unlike tacrine) 2
• Monitor for bladder outflow obstruction 1
• Caution in patients with asthma or obstructive pulmonary disease 1

Drug Interactions

Potential interactions (conflicting evidence) 2:

• Cimetidine
• Theophylline
• Warfarin
• Digoxin

Anesthesia consideration: Donepezil will exaggerate succinylcholine-type muscle relaxation 1

Alternative Therapies

If donepezil fails or is not tolerated, consider switching to another cholinesterase inhibitor as patients who don't respond to one may respond to another 2:

Rivastigmine

• Start 1.5 mg twice daily with food
• Increase by 3 mg/day every 4 weeks as tolerated
• Maximum 12 mg/day (6 mg twice daily)
• More GI side effects than donepezil but no drug interactions with common medications 2, 7

Galantamine

• Start 4 mg twice daily with meals
• Increase to 8 mg twice daily after 4 weeks
• Consider 12 mg twice daily based on benefit/tolerability
• Contraindicated in hepatic or renal impairment 2

Memantine

• For moderate to severe Alzheimer's disease, can be used alone or combined with cholinesterase inhibitors 7
• Provides additional benefit through NMDA receptor antagonism 8

Vitamin E

• 2,000 IU daily may slow functional decline based on expert consensus 2

Expected Benefits

Set realistic expectations with patients and families 2:

• Modest improvements: 5-15% benefit over placebo
• Equivalent to delaying decline by approximately one year
• Benefits include stabilization or slowed deterioration rather than dramatic improvement
• Approximately 20-35% of patients show meaningful response 2

Common Pitfalls

1. Escalating dose too quickly - Wait full 4-6 weeks before increasing from 5 to 10 mg, and 3 months before considering 23 mg 1
2. Not taking with food - Increases GI side effects unnecessarily 2
3. Discontinuing during behavioral symptoms - Don't stop if patient has active psychosis, agitation, or aggression unless symptoms worsened after starting/increasing donepezil 5
4. Using brief cognitive tests alone - These are insensitive measures; use comprehensive assessment including caregiver input 2
5. Jumping to 23 mg without intermediate titration - Significantly increases nausea risk 4